The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

Arcieri, Enyr Saran; Filho, P.T. P. Pierre; Wakamatsu, Tais Hitomi; Costa, Vital Paulino

doi:10.1038/sj.eye.6702542

“…Most of the recent studies have showed that prostaglandin analogues could decrease the central corneal thickness (CCT) values [13][14][15][16][17][18][19]. Lee and Cho [13] observed that latanoprost significantly reduced CCT in normal-tension glaucoma patients after 5 years of treatment.…”

Section: Resultsmentioning

confidence: 99%

The Effect of Prostaglandin Analogues on Central Corneal Thickness

Duygu¹

2018

Int J Ophthalmol Clin Res

View full text Add to dashboard Cite

• Page 1 of 6 • Uzunel. Int J Ophthalmol Clin Res 2018, 5:084 gested mechanism of IOP reduction involves aqueous humor outflow enhancement through the uveoscleral pathway accompanied by collagen degradation in the ciliary body. This collagen degradation is believed to be mediated by Matrix Metalloproteinases (MMPs) induced by prostaglandin F2-alpha [2,3]. Furthermore, because the cornea is mainly composed of collagen fiber [4], corneal thinning may be anticipated after pros-Elevated IOP is a risk factor for glaucoma and it's believed that to decrease the IOP values is the first choice of treatment in glaucoma [5]. Goldmann Applanation Tonometry (GAT) is known to be a standart method for IOP measurements however it's also well known that changes in Central Corneal Thickness (CCT) measurements may influence the GAT results accurate results of GAT are produced with a CCT of 520 mm, but CCT values higher or lower than 520 mm produces unreliable IOP measurements by over or under estimating of IOP values [6]. Besides its importance in IOP measurements it's also been suggested that CCT is an independent risk factor of progression in open angle glaucoma [7].The purpose of this study was to evaluate 5-year changes in the CCT in glaucoma patients treated with PG analogues monotherapy and to investigate the association between the CCT and the IOP in these patients. Material and MethodsMedical charts of 3696 glaucoma patients who have been followed up at Izmir Bozyaka Training and Research Hospital were reviewed retrospectively. Seventy-three eyes of 73 glaucoma patients constituted the glaucoma group and 75 eyes of 75 glaucoma-suspect patients constituted the control group. The inclusion

show abstract

“…Sen, et al [15] observed a significant reduction in CCT at the 6 th , 12 th , and 24 th months in 188 eyes of 94 patients under topical latanoprost and bimatoprost medications. Arcieri, et al [16] found a statistically significant CCT reduction (0.6%) in 34 glaucoma patients within the first month of bimatoprost treatment, but no change was observed in latanoprost and travoprost treatment groups. In 69 eyes, Zhong, et al [17] determined that topical therapy with PGs is associated with CCT reduction and latanoprost, travoprost, and bimatoprost have a similar effect on CCT.…”

Section: Resultsmentioning

confidence: 99%

Untitled

2018

Int J Ophthalmol Clin Res

0

View full text Add to dashboard Cite

• Page 1 of 6 • Uzunel. Int J Ophthalmol Clin Res 2018, 5:084 gested mechanism of IOP reduction involves aqueous humor outflow enhancement through the uveoscleral pathway accompanied by collagen degradation in the ciliary body. This collagen degradation is believed to be mediated by Matrix Metalloproteinases (MMPs) induced by prostaglandin F2-alpha [2,3]. Furthermore, because the cornea is mainly composed of collagen fiber [4], corneal thinning may be anticipated after pros-Elevated IOP is a risk factor for glaucoma and it's believed that to decrease the IOP values is the first choice of treatment in glaucoma [5]. Goldmann Applanation Tonometry (GAT) is known to be a standart method for IOP measurements however it's also well known that changes in Central Corneal Thickness (CCT) measurements may influence the GAT results accurate results of GAT are produced with a CCT of 520 mm, but CCT values higher or lower than 520 mm produces unreliable IOP measurements by over or under estimating of IOP values [6]. Besides its importance in IOP measurements it's also been suggested that CCT is an independent risk factor of progression in open angle glaucoma [7].The purpose of this study was to evaluate 5-year changes in the CCT in glaucoma patients treated with PG analogues monotherapy and to investigate the association between the CCT and the IOP in these patients. Material and MethodsMedical charts of 3696 glaucoma patients who have been followed up at Izmir Bozyaka Training and Research Hospital were reviewed retrospectively. Seventy-three eyes of 73 glaucoma patients constituted the glaucoma group and 75 eyes of 75 glaucoma-suspect patients constituted the control group. The inclusion

show abstract

“…more effective, reliable, probable, etc) than q, e.g., IOP reduction obtained with travoprost was significantly higher than that obtained with latanoprost [1]; p > q means that p is more preferred (but not significantly) than q, e.g., travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension [14]; and p q means p is more or less equivalently preferred to q, e.g., travoprost appears to be equivalent to bimatoprost and latanoprost [14]. It should be noted that p q does not simply lead to p > q since p > q implies that preference of p to q is not significant.…”

Section: Notations and Definitionsmentioning

confidence: 99%

“…The comparisons of drugs on IOP reduction are often expressed in the form of e.g. travoprost was superior to latanoprost [6] or travoprost appears to be equivalent to bimatoprost and latanoprost [14] or IOP reduction obtained with travoprost was significantly higher than that obtained with latanoprost [1] (note travoprost, bimatoprost, latanopros, and timolol are all names of drugs for IOP reduction).…”

Section: Introductionmentioning

confidence: 99%

“…Trial results are a summary of the underlying statistical analysis, usually there is a qualitative statement comparing two drugs of interest. For example, in [1,5,6,7,12,14], comparisons of different drugs on the efficacy of lowering intraocular pressure (called IOP reduction) are experimented. The comparisons of drugs on IOP reduction are often expressed in the form of e.g.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modeling and reasoning with qualitative comparative clinical knowledge

Ma

¹

,

Liu

²

,

Hunter

³

2010

Int. J. Intell. Syst.

View full text Add to dashboard Cite

The number of clinical trials reports is increasing rapidly due to a large number of clinical trials being conducted, it therefore raises an urgent need to utilize the clinical knowledge contained in the clinical trials reports. In this paper, we focus on the qualitative knowledge instead of quantitative knowledge. More precisely, we aim to model and reason with the qualitative comparison (QC for short) relations which consider qualitatively how strongly one drug/therapy is preferred to another in a clinical point of view. To this end, first, we formalize the QC relations, introduce the notions of QC language, QC base, and QC profile; second, we propose a set of induction rules for the QC relations, and provide grading interpretations for the QC bases and show how to determine whether a QC base is consistent. Furthermore, when a QC base is inconsistent, we analyze how to measure inconsistencies among QC bases, and we propose different approaches to merging multiple QC bases. Finally, a case study on lowering intraocular pressure is conducted to illustrate our approaches.

show abstract

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

Cited by 47 publications

References 30 publications

The Effect of Prostaglandin Analogues on Central Corneal Thickness

The Effect of Prostaglandin Analogues on Central Corneal Thickness

Untitled

Modeling and reasoning with qualitative comparative clinical knowledge

Contact Info

Product

Resources

About